18. Trade and other receivables and other current assets
|
31 December |
|
|---|---|---|
(thousands of €) |
2022 |
2021 |
Trade receivables |
28,194 |
91,786 |
Prepayments |
488 |
202 |
Other receivables |
11,747 |
19,349 |
Trade and other receivables |
40,429 |
111,337 |
Accrued income |
11,277 |
639 |
Deferred charges |
12,029 |
9,306 |
Other current assets |
23,307 |
9,945 |
Total trade and other receivables & other current assets |
63,735 |
121,282 |
Trade and other receivables decreased primarily due to the outstanding receivables as at 31 December 2021 of €50.0 million on Gilead related to the additional payments in the scope of the renegotiated agreement of December 2020 for filgotinib, and of €12.6 million ($15 million) on Gilead following the agreement for the take-over by us of the DIVERSITY clinical trial, which were both paid in 2022. We refer to note 2 Summary of significant transaction for more details.
We consider that the carrying amount of trade and other receivables approximates their fair value.
The other current assets mainly included accrued interest income and deferred charges.
On 31 December 2022, we did not have any provision for expected credit losses.